After several months of construction work, Cooper University Health Care unveiled its newly upgraded rooftop helipad and reopened for patient traffic on Friday, December 14, 2018. The helipad is one of the most heavily used in the region, as Cooper is a leading academic health center and serves as South Jersey’s only Level 1 Trauma Center. In addition to trauma patients, critically ill patients are also airlifted from other hospitals for a higher-level specialty care provided by Cooper’s physicians. Read more.
One of only two in New Jersey
Cooper University Health Care and Cooper Medical School of Rowan University recently received approval to establish an Otolaryngology-Head & Neck Surgery (ENT) residency program from the ACGME (Accreditation Council for Graduate Medical Education). This highly specialized surgical training program is only the second of its kind in New Jersey. ENT residency training is in high demand and typically one of the most competitive residency programs nationally. Read more.
Cooper University Health Care Chairman George E. Norcross, III, issued a statement commending and thanking the leaders of health systems in New Jersey and Pennsylvania for raising the minimum wage to $15 an hour for employees at their institutions.
“I want to thank our colleagues at the health systems that have joined Cooper in raising the minimum wage for their employees to a minimum of $15 an hour,” said Norcross. Read more.
A medical team at Cooper University Health Care recently was the first in the eastern United States to treat a patient with central sleep apnea (CSA) with a new implantable device to stimulate breathing. Cooper is currently one of only 24 sites in the United States treating CSA with the remedē® System, developed by medical technology company Respicardia, Inc. The remedē® System received FDA-approval in 2017 and is the first commercially available device to treat CSA. Read more.
The Coriell Institute for Medical Research, Cooper University Health Care and Cooper Medical School of Rowan University (CMSRU) are launching the Camden Opioid Research Initiative (CORI), a first-of-its-kind undertaking to investigate the genetic and biological factors that contribute to the development of opioid use disorder (also referred to as opioid dependence or addiction). Opioid overdoses continue to climb in New Jersey and nationally and the opioid addiction epidemic is one of the most urgent public health concerns of our time. Read more.
Memorial floragraph will be among several adorning the 2019 Donate Life Float at the 130th Rose ParadeTM on January 1, 2019, in Pasadena, California.
Family, loved ones, hospital staff, and representatives from the NJ Sharing Network gathered on November 16, 2018 to remember Tabernacle, NJ, teen Sean Clegg by completing a beautiful floragraph portrait that will be part of the 2019 Donate Life Float at the 130th Annual Rose ParadeTM in Pasadena, California, this coming New Year’s Day. Read more.
Wage Hike by Largest Employer in Camden City and County Will Benefit 10% of Workforce
Cooper University Health Care Chairman George E. Norcross, III today announced the health system will increase the minimum wage it pays employees to $15 an hour, the first health system in New Jersey to make such a commitment to its full-time, part-time, and per-diem employees. The new minimum wage policy will go into effect on January 1, 2019, and will benefit approximately 10 percent of Cooper’s 7,500 employees, one third of whom are Camden city residents and over 450 of whom are Camden County residents. Read more.
Cooper University Health Care and Advanced Recovery Systems (ARS), which operates addiction and substance abuse treatment centers in five states, announced the joining of forces to form a partnership to provide addiction recovery services to patients in the region. Together, ARS and Cooper are building a state-of-the-art, $27 million, 90-bed inpatient treatment facility in Cherry Hill, New Jersey; the first of several planned treatment facilities in the region. Read more.
Study explores if some patients may forego surgery after chemotherapy
MD Anderson Cancer Center at Cooper has joined a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery. This study, done in conjunction with The University of Texas MD Anderson Cancer Center in Houston, is led by principal investigator Henry M. Read more.
Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.